What one share of Alx Oncology Holdings holds
We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. Our clinical pipeline includes two clinical-stage product candidates, the CD47 blocker evorpacept and an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC) ALX2004.
Alx Oncology Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.94 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.82 |
| Cash and investments | $0.16 |
| Debt | $0.08 |
| Book value | $0.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.75 | −$6.33 | $0.24 | −$5.03 | — | −$18.82 |
| 2019 | $1.56 | −$7.56 | $0.11 | −$4.75 | — | −$22.31 |
| 2020 | $0.06 | −$2.76 | $0.00 | −$2.07 | — | — |
| 2021 | $0.00 | −$2.07 | $0.02 | −$1.71 | — | $8.94 |
| 2022 | $0.00 | −$3.03 | $0.04 | −$2.23 | — | $6.45 |
| 2023 | — | −$3.74 | $0.03 | −$3.06 | — | $3.80 |
| 2024 | — | −$2.58 | $0.01 | −$2.35 | — | $2.14 |
| 2025 | — | −$1.90 | $0.00 | −$1.57 | — | $0.48 |
Common questions about Alx Oncology Holdings
How much does one share of Alx Oncology Holdings earn?
Over the last 12 months, Alx Oncology Holdings lost $0.94 for each share.
Does Alx Oncology Holdings pay a dividend?
Alx Oncology Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Alx Oncology Holdings’s book value per share?
Alx Oncology Holdings’s book value is $0.99 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Alx Oncology Holdings have?
Each share of Alx Oncology Holdings has $0.16 of cash and investments and $0.08 of debt, as of June 30, 2026.
What is Alx Oncology Holdings’s free cash flow per share?
−$0.82 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Alx Oncology Holdings bought back shares?
Alx Oncology Holdings’s share count rose about 1851% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.